Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.
According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.
Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.
Related Articles
Amazon.com, Inc. (AMZN.US) stock price hits three-year high, analysts raise target price to $290.
US Stock Market Move | Tesla, Inc. (TSLA.US) rose nearly 4% as Morgan Stanley significantly raised its target price to $800.
Alphabet (GOOG.US, GOOGL.US) performance greatly exceeds expectations, stock price reaching all-time high. Analysts unanimously bullish on its AI and cloud business.
Amazon.com, Inc. (AMZN.US) stock price hits three-year high, analysts raise target price to $290.
US Stock Market Move | Tesla, Inc. (TSLA.US) rose nearly 4% as Morgan Stanley significantly raised its target price to $800.
Alphabet (GOOG.US, GOOGL.US) performance greatly exceeds expectations, stock price reaching all-time high. Analysts unanimously bullish on its AI and cloud business.
RECOMMEND
First in History: NVIDIA’s Market Capitalization Tops $5 Trillion
30/10/2025
Congressional Budget Office Estimates Government Shutdown Has Cost the U.S. Economy $18 Billion
30/10/2025
Wall Street on China’s Internet Sector: Distinct Investment Opportunities in AI and Gaming; Caution on E‑commerce
30/10/2025
